^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Myelodysplastic Syndrome
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Roche Press Release
    Title:

    FDA Grants Breakthrough Therapy Designation for Venclexta in Combination With Azacitidine for the Treatment of Patients With Myelodysplastic Syndromes

    Published date:
    07/20/2021
    Excerpt:
    Genentech, a member of the Roche Group...today announced that Venclexta® (venetoclax) in combination with azacitidine has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with previously untreated intermediate, high- and very high-risk myelodysplastic syndromes (MDS)...
    Secondary therapy:
    azacitidine